25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Atea Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Atea Pharmaceuticals Inc together

I guess you are interested in Atea Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Atea Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Atea Pharmaceuticals Inc

I send you an email if I find something interesting about Atea Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Atea Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Atea Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.43
Expected worth in 1 year
$3.97
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-1.46
Return On Investment
-43.8%

For what price can you sell your share?

Current Price per Share
$3.33
Expected price per share
$2.88 - $3.62
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Atea Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$3.33
Intrinsic Value Per Share
$-36.58 - $-43.41
Total Value Per Share
$-31.16 - $-37.98

2.2. Growth of Atea Pharmaceuticals Inc (5 min.)




Is Atea Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$458.5m$610.7m-$112m-22.5%

How much money is Atea Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$43.5m-$32.8m-$10.6m-24.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Atea Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#136 / 933

Most Revenue
#856 / 933

Most Profit
#792 / 933

Most Efficient
#244 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Atea Pharmaceuticals Inc?

Welcome investor! Atea Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Atea Pharmaceuticals Inc.

First you should know what it really means to hold a share of Atea Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Atea Pharmaceuticals Inc is $3.33. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Atea Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Atea Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.43. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Atea Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.37-11.1%-0.52-15.5%-0.39-11.7%-0.17-5.1%-0.17-5.1%
Usd Book Value Change Per Share-0.21-6.4%-0.36-11.0%-0.24-7.2%0.278.2%0.278.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-6.4%-0.36-11.0%-0.24-7.2%0.278.2%0.278.2%
Usd Price Per Share3.35-3.44-3.73-10.88-10.88-
Price to Earnings Ratio-2.27--1.75--2.41-16.63-16.63-
Price-to-Total Gains Ratio-15.76--10.55--15.71-36.92-36.92-
Price to Book Ratio0.62-0.59-0.51-1.62-1.62-
Price-to-Total Gains Ratio-15.76--10.55--15.71-36.92-36.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.33
Number of shares300
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.360.27
Usd Total Gains Per Share-0.360.27
Gains per Quarter (300 shares)-109.4081.43
Gains per Year (300 shares)-437.62325.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-438-4480326316
20-875-8860651642
30-1313-13240977968
40-1750-1762013031294
50-2188-2200016291620
60-2626-2638019541946
70-3063-3076022802272
80-3501-3514026062598
90-3939-3952029312924
100-4376-4390032573250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%4.016.00.020.0%4.016.00.020.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%8.012.00.040.0%8.012.00.040.0%8.012.00.040.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%8.012.00.040.0%8.012.00.040.0%8.012.00.040.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Atea Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.213-0.365+72%-0.241+13%0.271-178%0.271-178%
Book Value Per Share--5.4295.904-8%7.230-25%5.542-2%5.542-2%
Current Ratio--19.32917.468+11%39.320-51%19.706-2%19.706-2%
Debt To Asset Ratio--0.0660.072-8%0.038+74%0.353-81%0.353-81%
Debt To Equity Ratio--0.0710.078-9%0.039+79%0.140-50%0.140-50%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--733328398.400777801920.000-6%908194062.400-19%1761663928.792-58%1761663928.792-58%
Eps---0.369-0.515+40%-0.388+5%-0.170-54%-0.170-54%
Ev To Ebitda Ratio---4.928-4.261-14%-5.802+18%3.709-233%3.709-233%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.273-0.376+38%-0.246-10%-0.070-74%-0.070-74%
Free Cash Flow To Equity Per Share---0.271-0.375+38%-0.245-10%0.233-216%0.233-216%
Gross Profit Margin--1.0001.0020%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---43.413--------
Intrinsic Value_10Y_min---36.584--------
Intrinsic Value_1Y_max---1.931--------
Intrinsic Value_1Y_min---1.895--------
Intrinsic Value_3Y_max---7.645--------
Intrinsic Value_3Y_min---7.261--------
Intrinsic Value_5Y_max---15.582--------
Intrinsic Value_5Y_min---14.304--------
Market Cap281262136.320-1%282951398.400290341920.000-3%314625062.400-10%948324493.034-70%948324493.034-70%
Net Profit Margin----0%-0%0.033-100%0.033-100%
Operating Margin----0%-0%0.049-100%0.049-100%
Operating Ratio----0%-0%0.333-100%0.333-100%
Pb Ratio0.613-1%0.6170.586+5%0.513+20%1.623-62%1.623-62%
Pe Ratio-2.257+1%-2.271-1.748-23%-2.414+6%16.633-114%16.633-114%
Price Per Share3.330-1%3.3503.438-3%3.725-10%10.884-69%10.884-69%
Price To Free Cash Flow Ratio-3.053+1%-3.071-2.454-20%-4.013+31%-5.854+91%-5.854+91%
Price To Total Gains Ratio-15.670+1%-15.764-10.552-33%-15.7110%36.920-143%36.920-143%
Quick Ratio--34.42529.151+18%65.776-48%28.772+20%28.772+20%
Return On Assets---0.063-0.081+27%-0.052-19%-0.057-10%-0.057-10%
Return On Equity---0.068-0.087+28%-0.054-21%-0.041-40%-0.041-40%
Total Gains Per Share---0.213-0.365+72%-0.241+13%0.271-178%0.271-178%
Usd Book Value--458521000.000498638500.000-8%610708250.000-25%473336300.000-3%473336300.000-3%
Usd Book Value Change Per Share---0.213-0.365+72%-0.241+13%0.271-178%0.271-178%
Usd Book Value Per Share--5.4295.904-8%7.230-25%5.542-2%5.542-2%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--733328398.400777801920.000-6%908194062.400-19%1761663928.792-58%1761663928.792-58%
Usd Eps---0.369-0.515+40%-0.388+5%-0.170-54%-0.170-54%
Usd Free Cash Flow---23035000.000-31734000.000+38%-20790750.000-10%-5285400.000-77%-5285400.000-77%
Usd Free Cash Flow Per Share---0.273-0.376+38%-0.246-10%-0.070-74%-0.070-74%
Usd Free Cash Flow To Equity Per Share---0.271-0.375+38%-0.245-10%0.233-216%0.233-216%
Usd Market Cap281262136.320-1%282951398.400290341920.000-3%314625062.400-10%948324493.034-70%948324493.034-70%
Usd Price Per Share3.330-1%3.3503.438-3%3.725-10%10.884-69%10.884-69%
Usd Profit---31151000.000-43501500.000+40%-32805750.000+5%-14051050.000-55%-14051050.000-55%
Usd Revenue----0%-0%20000000.000-100%20000000.000-100%
Usd Total Gains Per Share---0.213-0.365+72%-0.241+13%0.271-178%0.271-178%
 EOD+3 -5MRQTTM+21 -12YOY+9 -235Y+7 -3010Y+7 -30

3.3 Fundamental Score

Let's check the fundamental score of Atea Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.257
Price to Book Ratio (EOD)Between0-10.613
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than134.425
Current Ratio (MRQ)Greater than119.329
Debt to Asset Ratio (MRQ)Less than10.066
Debt to Equity Ratio (MRQ)Less than10.071
Return on Equity (MRQ)Greater than0.15-0.068
Return on Assets (MRQ)Greater than0.05-0.063
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Atea Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.405
Ma 20Greater thanMa 503.287
Ma 50Greater thanMa 1003.262
Ma 100Greater thanMa 2003.422
OpenGreater thanClose3.310
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-01-16 13:33:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Atea Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atea Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y3.3%-3.3%
5Y3.3%10Y3.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--104.6%+104.6%
TTM--216.4%+216.4%
YOY--208.6%+208.6%
5Y3.3%-353.9%+357.2%
10Y3.3%-488.0%+491.3%
4.3.1.2. Return on Assets

Shows how efficient Atea Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • -6.3% Return on Assets means that Atea Pharmaceuticals Inc generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atea Pharmaceuticals Inc:

  • The MRQ is -6.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.3%TTM-8.1%+1.7%
TTM-8.1%YOY-5.2%-2.9%
TTM-8.1%5Y-5.7%-2.4%
5Y-5.7%10Y-5.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.3%-12.7%+6.4%
TTM-8.1%-13.0%+4.9%
YOY-5.2%-12.3%+7.1%
5Y-5.7%-13.7%+8.0%
10Y-5.7%-15.7%+10.0%
4.3.1.3. Return on Equity

Shows how efficient Atea Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • -6.8% Return on Equity means Atea Pharmaceuticals Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atea Pharmaceuticals Inc:

  • The MRQ is -6.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.8%TTM-8.7%+1.9%
TTM-8.7%YOY-5.4%-3.3%
TTM-8.7%5Y-4.1%-4.6%
5Y-4.1%10Y-4.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.8%-16.8%+10.0%
TTM-8.7%-17.8%+9.1%
YOY-5.4%-16.4%+11.0%
5Y-4.1%-20.6%+16.5%
10Y-4.1%-21.2%+17.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Atea Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Atea Pharmaceuticals Inc is operating .

  • Measures how much profit Atea Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atea Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y4.9%-4.9%
5Y4.9%10Y4.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--193.6%+193.6%
TTM--321.1%+321.1%
YOY--227.9%+227.9%
5Y4.9%-373.0%+377.9%
10Y4.9%-506.1%+511.0%
4.3.2.2. Operating Ratio

Measures how efficient Atea Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atea Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.333-0.333
5Y0.33310Y0.3330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.171-2.171
TTM-3.250-3.250
YOY-3.231-3.231
5Y0.3334.838-4.505
10Y0.3336.440-6.107
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Atea Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Atea Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.33 means the company has $19.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atea Pharmaceuticals Inc:

  • The MRQ is 19.329. The company is very able to pay all its short-term debts. +2
  • The TTM is 17.468. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.329TTM17.468+1.861
TTM17.468YOY39.320-21.852
TTM17.4685Y19.706-2.237
5Y19.70610Y19.7060.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.3293.610+15.719
TTM17.4683.850+13.618
YOY39.3204.605+34.715
5Y19.7065.895+13.811
10Y19.7066.178+13.528
4.4.3.2. Quick Ratio

Measures if Atea Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 34.42 means the company can pay off $34.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atea Pharmaceuticals Inc:

  • The MRQ is 34.425. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 29.151. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ34.425TTM29.151+5.274
TTM29.151YOY65.776-36.625
TTM29.1515Y28.772+0.379
5Y28.77210Y28.7720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.4253.034+31.391
TTM29.1513.355+25.796
YOY65.7764.297+61.479
5Y28.7725.890+22.882
10Y28.7726.434+22.338
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Atea Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Atea Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Atea Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Atea Pharmaceuticals Inc assets are financed with 6.6% credit (debt) and the remaining percentage (100% - 6.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Atea Pharmaceuticals Inc:

  • The MRQ is 0.066. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.072. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.066TTM0.072-0.006
TTM0.072YOY0.038+0.034
TTM0.0725Y0.353-0.281
5Y0.35310Y0.3530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0660.341-0.275
TTM0.0720.343-0.271
YOY0.0380.310-0.272
5Y0.3530.366-0.013
10Y0.3530.385-0.032
4.5.4.2. Debt to Equity Ratio

Measures if Atea Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 7.1% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atea Pharmaceuticals Inc:

  • The MRQ is 0.071. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.078. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.071TTM0.078-0.007
TTM0.078YOY0.039+0.038
TTM0.0785Y0.140-0.063
5Y0.14010Y0.1400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0710.393-0.322
TTM0.0780.429-0.351
YOY0.0390.382-0.343
5Y0.1400.439-0.299
10Y0.1400.489-0.349
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atea Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Atea Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -2.27 means the investor is paying $-2.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atea Pharmaceuticals Inc:

  • The EOD is -2.257. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.271. Based on the earnings, the company is expensive. -2
  • The TTM is -1.748. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.257MRQ-2.271+0.014
MRQ-2.271TTM-1.748-0.523
TTM-1.748YOY-2.414+0.667
TTM-1.7485Y16.633-18.381
5Y16.63310Y16.6330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.257-2.247-0.010
MRQ-2.271-2.693+0.422
TTM-1.748-3.214+1.466
YOY-2.414-3.335+0.921
5Y16.633-6.368+23.001
10Y16.633-6.692+23.325
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Atea Pharmaceuticals Inc:

  • The EOD is -3.053. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.071. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.454. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.053MRQ-3.071+0.018
MRQ-3.071TTM-2.454-0.617
TTM-2.454YOY-4.013+1.559
TTM-2.4545Y-5.854+3.400
5Y-5.85410Y-5.8540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.053-2.993-0.060
MRQ-3.071-3.671+0.600
TTM-2.454-4.037+1.583
YOY-4.013-4.482+0.469
5Y-5.854-8.190+2.336
10Y-5.854-9.383+3.529
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Atea Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.62 means the investor is paying $0.62 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atea Pharmaceuticals Inc:

  • The EOD is 0.613. Based on the equity, the company is cheap. +2
  • The MRQ is 0.617. Based on the equity, the company is cheap. +2
  • The TTM is 0.586. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.613MRQ0.617-0.004
MRQ0.617TTM0.586+0.031
TTM0.586YOY0.513+0.073
TTM0.5865Y1.623-1.037
5Y1.62310Y1.6230.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6131.933-1.320
MRQ0.6172.265-1.648
TTM0.5862.447-1.861
YOY0.5132.454-1.941
5Y1.6233.664-2.041
10Y1.6234.239-2.616
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atea Pharmaceuticals Inc.

4.8.1. Institutions holding Atea Pharmaceuticals Inc

Institutions are holding 71.117% of the shares of Atea Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30BlackRock Inc10.64460.00068990734-129829-1.4235
2024-09-30BML Capital Management LLC7.873313.108366500002743794.3036
2024-09-30FMR Inc7.83570.001466182971821742.8305
2024-09-30EcoR1 Capital, LLC6.44290.624544189600
2024-09-30Vanguard Group Inc5.74360.000348512181268132.6842
2024-09-30TANG CAPITAL MANAGEMENT LLC5.45451.102546070601303192.911
2024-09-30Bain Capital Life Sciences Investors, LLC2.94290.8663248563800
2024-09-30Geode Capital Management, LLC2.27880.00051924773-85030-4.2308
2024-09-30State Street Corp2.05240.00021733486115660.6717
2024-09-30Almitas Capital LLC1.63921.6391384529943427.3123
2024-09-30Renaissance Technologies Corp1.42910.00611207100656005.7468
2024-09-30Dimensional Fund Advisors, Inc.0.93960.000679362619926633.5261
2024-09-30Northern Trust Corp0.81390.0004687438261543.955
2024-09-30Charles Schwab Investment Management Inc0.76980.0004650157507948.4747
2024-09-30Citadel Advisors Llc0.70470.00045952496964613.2507
2024-09-30Two Sigma Advisers, LLC0.68950.0046582400-29800-4.8677
2024-09-30Federated Hermes Inc0.67730.00425720838150.1427
2024-09-30Jacobs Levy Equity Management, Inc.0.60320.0066509471-55427-9.8119
2024-09-30Morgan Stanley - Brokerage Accounts0.57880.0001488899-246181-33.4904
2024-09-30Newtyn Management LLC0.44990.195438000000
Total 60.563717.561951154054+685601+1.3%

4.9.2. Funds holding Atea Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Fidelity Growth Compy Commingled Pl S4.54250.014383677346120.1203
2024-11-30Vanguard Total Stock Mkt Idx Inv2.79810.0004236332700
2024-12-31iShares Russell 2000 ETF2.4490.00962068527-7950-0.3829
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr1.52080.00361284504179071.4138
2024-11-30Fidelity Growth Company Fund1.13590.0047959424-2342-0.2435
2024-10-31Fidelity Small Cap Index0.910.0093768638-550-0.0715
2024-11-30Fidelity Growth Company K60.8740.0118738219-2270-0.3066
2024-12-31iShares Russell 2000 Value ETF0.8690.0199733956-20538-2.7221
2024-11-30Fidelity Select Biotechnology0.78980.048667100-138252-17.1667
2024-11-30BlackRock Advantage Small Cap Core Instl0.78620.050866408700
2024-12-31iShares Biotechnology ETF0.56310.0248475584-3430-0.7161
2024-12-31State St Russell Sm/Mid CpÂź Indx NL Cl C0.55840.0035471666-7600-1.5858
2024-09-30Federated Hermes MDT Small Cap Core IS0.49920.101542164200
2024-09-30Federated Hermes MDT SCC Institutional0.49920.101442164200
2024-11-30Fidelity Extended Market Index0.49860.0032421105-2776-0.6549
2024-12-31Schwab US Small-Cap ETFℱ0.45480.00738414000
2024-11-30Vanguard Russell 2000 ETF0.42870.008936212596202.729
2024-12-31State St Russell Sm CapÂź Indx SL Cl I0.35440.010529930400
2024-09-30Vanguard Strategic Equity Inv0.32960.010327840800
2024-11-30Vanguard Health Care ETF0.24770.0035209203-897-0.4269
Total 21.1090.446717829374-154466-0.9%

5.3. Insider Transactions

Insiders are holding 9.566% of the shares of Atea Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-10Franklin M BergerSELL3596062.85
2024-09-19Jean-pierre SommadossiSELL18414
2024-09-17Jean-pierre SommadossiSELL339414.05
2024-06-20Bruce PolskySELL175443.49
2024-06-05Jean-pierre SommadossiSELL10064
2024-02-01Andrea CorcoranSELL158433.84
2024-02-01Jean-pierre SommadossiSELL569103.85
2024-02-01Wayne FosterSELL124773.84
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets490,957
Total Liabilities32,436
Total Stockholder Equity458,521
 As reported
Total Liabilities 32,436
Total Stockholder Equity+ 458,521
Total Assets = 490,957

Assets

Total Assets490,957
Total Current Assets486,906
Long-term Assets4,051
Total Current Assets
Cash And Cash Equivalents 98,463
Short-term Investments 384,350
Other Current Assets 4,093
Total Current Assets  (as reported)486,906
Total Current Assets  (calculated)486,906
+/-0
Long-term Assets
Property Plant Equipment 2,368
Long-term Assets Other 1,683
Long-term Assets  (as reported)4,051
Long-term Assets  (calculated)4,051
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities25,190
Long-term Liabilities7,246
Total Stockholder Equity458,521
Total Current Liabilities
Short-term Debt 790
Accounts payable 5,785
Other Current Liabilities 12,414
Total Current Liabilities  (as reported)25,190
Total Current Liabilities  (calculated)18,989
+/- 6,201
Long-term Liabilities
Long-term Liabilities  (as reported)7,246
Long-term Liabilities  (calculated)0
+/- 7,246
Total Stockholder Equity
Common Stock84
Retained Earnings -330,677
Other Stockholders Equity 789,114
Total Stockholder Equity (as reported)458,521
Total Stockholder Equity (calculated)458,521
+/-0
Other
Cash and Short Term Investments 482,813
Common Stock Shares Outstanding 84,422
Current Deferred Revenue6,201
Liabilities and Stockholders Equity 490,957
Net Debt -96,628
Net Working Capital 461,716
Short Long Term Debt Total 1,835



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302018-03-312017-12-31
> Total Assets 
0
0
0
0
0
0
0
22,073
17,753
119,745
110,106
863,632
840,649
871,543
843,504
772,892
717,189
694,338
686,576
666,708
638,131
626,028
608,075
594,968
553,029
510,384
490,957
490,957510,384553,029594,968608,075626,028638,131666,708686,576694,338717,189772,892843,504871,543840,649863,632110,106119,74517,75322,0730000000
   > Total Current Assets 
0
0
0
0
0
0
0
21,910
17,587
118,450
108,413
863,477
840,145
871,110
842,946
772,403
713,232
689,451
681,935
660,922
632,390
620,826
603,316
590,455
548,764
506,369
486,906
486,906506,369548,764590,455603,316620,826632,390660,922681,935689,451713,232772,403842,946871,110840,145863,477108,413118,45017,58721,9100000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
21,661
17,147
115,792
105,383
850,117
833,751
816,460
839,660
764,375
705,545
684,480
176,410
646,709
183,255
213,700
137,886
143,823
160,910
243,394
98,463
98,463243,394160,910143,823137,886213,700183,255646,709176,410684,480705,545764,375839,660816,460833,751850,117105,383115,79217,14721,6610000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
488,565
458,249
437,233
394,362
457,240
434,283
380,581
258,820
384,350
384,350258,820380,581434,283457,240394,362437,233458,249488,565000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
5,815
0
50,000
0
0
0
0
4,514
0
0
0
0
0
0
0
0
000000004,514000050,00005,81500000000000
       Other Current Assets 
0
0
0
0
0
0
0
249
440
2,658
3,030
7,545
6,394
4,650
3,286
8,028
7,687
4,971
12,446
14,213
11,902
12,764
8,190
12,349
7,273
4,155
4,093
4,0934,1557,27312,3498,19012,76411,90214,21312,4464,9717,6878,0283,2864,6506,3947,5453,0302,6584402490000000
   > Long-term Assets 
0
0
0
0
0
0
0
163
166
1,295
1,693
155
504
433
558
489
3,957
4,887
4,641
5,786
5,741
5,202
4,759
4,513
4,265
4,015
4,051
4,0514,0154,2654,5134,7595,2025,7415,7864,6414,8873,9574895584335041551,6931,2951661630000000
       Property Plant Equipment 
0
0
0
0
0
0
0
41
37
39
49
48
41
33
26
23
3,652
4,582
4,336
4,094
3,852
3,608
3,363
3,117
2,869
2,619
2,368
2,3682,6192,8693,1173,3633,6083,8524,0944,3364,5823,6522326334148493937410000000
       Other Assets 
0
0
0
0
0
0
0
0
129
1,256
1,644
107
107
400
305
466
305
305
0
1,692
1,889
1,594
0
0
0
0
0
000001,5941,8891,69203053054663054001071071,6441,25612900000000
> Total Liabilities 
0
0
0
0
0
0
0
71,644
1,927
7,127
186,617
315,831
254,391
273,682
262,052
62,815
37,305
33,881
23,389
26,136
19,949
23,679
26,345
39,776
48,658
33,914
32,436
32,43633,91448,65839,77626,34523,67919,94926,13623,38933,88137,30562,815262,052273,682254,391315,831186,6177,1271,92771,6440000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
2,435
1,927
7,058
10,816
315,795
254,278
273,653
262,052
56,883
28,610
25,107
15,634
18,478
12,361
16,159
18,893
32,376
41,311
26,619
25,190
25,19026,61941,31132,37618,89316,15912,36118,47815,63425,10728,61056,883262,052273,653254,278315,79510,8167,0581,9272,4350000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
7,200
12,002
197
113
730
711
721
730
740
750
760
1,538
1,560
790
7901,5601,53876075074073072171173011319712,0027,2000000000000000
       Accounts payable 
0
0
0
0
0
0
0
548
398
3,860
4,476
60
3,792
10,701
22,190
4,534
3,657
13,885
1,118
2,551
700
3,962
395
4,252
21,137
5,470
5,785
5,7855,47021,1374,2523953,9627002,5511,11813,8853,6574,53422,19010,7013,792604,4763,8603985480000000
       Other Current Liabilities 
0
0
0
0
0
0
0
1,887
1,529
3,198
6,340
14,368
15,104
30,761
35,680
52,152
24,840
10,492
13,805
15,206
10,931
5,963
12,131
27,364
12,734
13,539
12,414
12,41413,53912,73427,36412,1315,96310,93115,20613,80510,49224,84052,15235,68030,76115,10414,3686,3403,1981,5291,8870000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
69,209
0
69
175,801
36
113
29
0
5,932
8,695
8,774
7,755
7,658
7,588
7,520
7,452
7,400
7,347
7,295
7,246
7,2467,2957,3477,4007,4527,5207,5887,6587,7558,7748,6955,93202911336175,80169069,2090000000
       Other Liabilities 
0
0
0
0
0
0
0
0
82
69
56
36
0
29
0
5,932
5,932
6,008
5,170
5,255
5,373
5,494
0
0
0
0
0
000005,4945,3735,2555,1706,0085,9325,93202903656698200000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
1,149
1,537
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,5371,149000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
-49,571
15,744
112,618
-76,511
547,801
586,258
597,861
581,452
710,077
679,884
660,457
663,187
640,572
618,182
602,349
581,730
555,192
504,371
476,470
458,521
458,521476,470504,371555,192581,730602,349618,182640,572663,187660,457679,884710,077581,452597,861586,258547,801-76,511112,61815,744-49,5710000000
   Common Stock
0
0
0
0
0
0
0
10
10
59
10
82
83
83
83
83
83
83
83
83
83
83
83
83
84
84
84
84848483838383838383838383838382105910100000000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
-65,160
-34,447
-32,908
-61,102
56,030
13,953
-17,382
-25,448
0
-95,346
-123,529
0
0
0
0
0
00000-123,529-95,3460-25,448-17,38213,95356,030-61,102-32,908-34,447-65,16000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-175,745
-175,745
0
0
0
0
0
0
0
-855
-684
-307
-310
-262
207
-181
-280
641
641-280-181207-262-310-307-684-8550000000-175,745-175,745000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
612,879
620,622
630,686
642,471
653,964
665,848
677,756
689,407
0
713,752
726,105
0
0
0
0
0
00000726,105713,7520689,407677,756665,848653,964642,471630,686620,622612,87900000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
-64,482
4,821
5,008
9,295
612,879
620,622
630,686
642,471
653,964
665,848
677,756
689,407
701,052
713,752
726,105
738,580
750,737
763,472
776,192
789,114
789,114776,192763,472750,737738,580726,105713,752701,052689,407677,756665,848653,964642,471630,686620,622612,8799,2955,0084,821-64,4820000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-70,090
Gross Profit-70,090-70,090
 
Operating Income (+$)
Gross Profit-70,090
Operating Expense-94,072
Operating Income-164,162-164,162
 
Operating Expense (+$)
Research Development132,843
Selling General Administrative49,919
Selling And Marketing Expenses49,453
Operating Expense94,072232,215
 
Net Interest Income (+$)
Interest Income29,224
Interest Expense-0
Other Finance Cost-0
Net Interest Income29,224
 
Pretax Income (+$)
Operating Income-164,162
Net Interest Income29,224
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-134,938-193,386
EBIT - interestExpense = -120,009
-134,938
-135,956
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-120,009-134,938
Earnings Before Interest and Taxes (EBITDA)-119,593
 
After tax Income (+$)
Income Before Tax-134,938
Tax Provision-1,018
Net Income From Continuing Ops-135,956-135,956
Net Income-135,956
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses164,162
Total Other Income/Expenses Net29,224-29,224
 

Technical Analysis of Atea Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Atea Pharmaceuticals Inc. The general trend of Atea Pharmaceuticals Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Atea Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Atea Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.54 < 3.599 < 3.62.

The bearish price targets are: 2.88 > 2.88 > 2.88.

Tweet this
Atea Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Atea Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Atea Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Atea Pharmaceuticals Inc. The current macd is 0.0172952.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Atea Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Atea Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Atea Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Atea Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAtea Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Atea Pharmaceuticals Inc. The current adx is 14.55.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Atea Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Atea Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Atea Pharmaceuticals Inc. The current sar is 3.51871208.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Atea Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Atea Pharmaceuticals Inc. The current rsi is 53.41. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Atea Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAtea Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Atea Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Atea Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Atea Pharmaceuticals Inc Daily Stochastic Oscillator ChartAtea Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Atea Pharmaceuticals Inc. The current cci is 33.87.

Atea Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAtea Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Atea Pharmaceuticals Inc. The current cmo is 9.29926524.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Atea Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAtea Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Atea Pharmaceuticals Inc. The current willr is -55.01022495.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Atea Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Atea Pharmaceuticals Inc Daily Williams %R ChartAtea Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Atea Pharmaceuticals Inc. The current atr is 0.14615356.

Atea Pharmaceuticals Inc Daily Average True Range (ATR) ChartAtea Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Atea Pharmaceuticals Inc. The current obv is 169,800.

Atea Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAtea Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Atea Pharmaceuticals Inc. The current mfi is 52.84.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Atea Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAtea Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Atea Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-17BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Atea Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Atea Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.405
Ma 20Greater thanMa 503.287
Ma 50Greater thanMa 1003.262
Ma 100Greater thanMa 2003.422
OpenGreater thanClose3.310
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Atea Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Atea Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Atea Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Atea Pharmaceuticals Inc

I send you an email if I find something interesting about Atea Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Atea Pharmaceuticals Inc.

Receive notifications about Atea Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.